Your browser doesn't support javascript.
loading
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
Jahn, A; Rump, A; Widmann, T J; Heining, C; Horak, P; Hutter, B; Paramasivam, N; Uhrig, S; Gieldon, L; Drukewitz, S; Kübler, A; Bermudez, M; Hackmann, K; Porrmann, J; Wagner, J; Arlt, M; Franke, M; Fischer, J; Kowalzyk, Z; William, D; Weth, V; Oster, S; Fröhlich, M; Hüllein, J; Valle González, C; Kreutzfeldt, S; Mock, A; Heilig, C E; Lipka, D B; Möhrmann, L; Hanf, D; Oles, M; Teleanu, V; Allgäuer, M; Ruhnke, L; Kutz, O; Knurr, A; Laßmann, A; Endris, V; Neumann, O; Penzel, R; Beck, K; Richter, D; Winter, U; Wolf, S; Pfütze, K; Geörg, C; Meißburger, B; Buchhalter, I; Augustin, M.
Afiliação
  • Jahn A; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germ
  • Rump A; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germ
  • Widmann TJ; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germ
  • Heining C; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresde
  • Horak P; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Hutter B; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany.
  • Paramasivam N; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Uhrig S; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany.
  • Gieldon L; Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany.
  • Drukewitz S; German Cancer Consortium (DKTK) Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany.
  • Kübler A; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Bermudez M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Hackmann K; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Porrmann J; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Wagner J; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Arlt M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Franke M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Fischer J; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • Kowalzyk Z; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospita
  • William D; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germ
  • Weth V; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany.
  • Oster S; German Cancer Consortium (DKTK) Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany.
  • Fröhlich M; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany.
  • Hüllein J; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany.
  • Valle González C; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany; University of Seville, Seville, Spain.
  • Kreutzfeldt S; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Mock A; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Medical Oncology, NCT Heidelberg and Heidelberg University Hospital, He
  • Heilig CE; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Lipka DB; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Möhrmann L; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresde
  • Hanf D; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresde
  • Oles M; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Teleanu V; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital,
  • Allgäuer M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Ruhnke L; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Kutz O; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany.
  • Knurr A; Department of Medical Informatics for Translational Oncology, DKFZ, Heidelberg, Germany.
  • Laßmann A; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Endris V; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Neumann O; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Penzel R; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Beck K; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Richter D; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresde
  • Winter U; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Wolf S; German Cancer Consortium (DKTK), Heidelberg, Germany; High-Throughput Sequencing Unit, Genomics and Proteomics Core Facility, DKFZ, Heidelberg, Germany.
  • Pfütze K; German Cancer Consortium (DKTK), Heidelberg, Germany; Sample Processing Laboratory, Molecular Diagnostics Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Geörg C; German Cancer Consortium (DKTK), Heidelberg, Germany; Sample Processing Laboratory, Molecular Diagnostics Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Meißburger B; German Cancer Consortium (DKTK), Heidelberg, Germany; Sample Processing Laboratory, Molecular Diagnostics Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Buchhalter I; Omics IT and Data Management Core Facility, DKFZ, Heidelberg, Germany.
  • Augustin M; Department of Hematology and Oncology, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany.
Ann Oncol ; 33(11): 1186-1199, 2022 11.
Article em En | MEDLINE | ID: mdl-35988656
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Ano de publicação: 2022 Tipo de documento: Article